Personalised medicine

Computerised tailor-made retinopathy therapy

Nowadays the concept of personalised medicine is usually applied to oncology. However, there are other clinical disciplines in which therapies tailored to the individual patient are within reach, viz. ophthalmology. In the researchers’ limelight is intravitreal drug delivery since the outcomes of injections into the vitreous differ from patient to patient. Ophthalmologists in Vienna, Austria, are working on software to identify suitable therapy for each individual patient.

Report: Michael Krassnitzer

An intravitreal injection (IVI)
An intravitreal injection (IVI)
Source: MUW
Sebastian M Waldstein
Sebastian M Waldstein

Intravitreal injections (IVI) are indicated for retinopathies such as age-related macular degeneration (AMD), diabetic macular oedema (DME) or retinal vascular occlusions. Antibodies are injected directly into the vitreous, which serves as a drug reservoir, and released to the retina over the course of a few weeks. Thus, for the first time retinal diseases can be treated directly – and successfully.

Thanks to intravitreal injections AMD is no longer the prime cause of blindness. However, there is a catch: In order to be on the safe side, the treatment must be repeated every few weeks – for life. ‘This is de facto impossible,’ says Dr Sebastian Waldstein, ophthalmologist at the Department of Ophthalmology and Optometry at the Medical University of Vienna, who is also in charge of the research focus Macular Degeneration at Vienna Reading Centre (VRC). ‘First, most patients simply cannot afford the monthly treatment financially,’ he points out, adding that it is also too stressful for the patient.’

Indeed, only a minority of patients need monthly treatment, he says. ‘For about two thirds of patients much longer intervals are entirely sufficient – in fact, some patients need only a few injections.’ Even better, ‘The course of retinal disease and the best treatment strategy can be predicted with a probability of ninety-nine percent probability’ using optical coherence tomography (OCT), a diagnostic procedure largely developed in Vienna, that has revolutionised ophthalmology within a few years. In OCT, hundreds of scans are combined to produce a 3-D image of the retina, which in turn allows reconstruction of the macula within seconds. However, the computing power behind this contactless procedure also poses a problem: the data volume generated in OCT is so huge that the ophthalmologist can no longer interpret it. To eliminate this quandary, Dr Waldstein is developing innovative computer-based methods to analyse large clinical image data sets.

To provide his research with an institutional framework, he initiated the Christian Doppler Laboratory for Ophthalmological Image Analysis, which he currently coordinates under the supervision of Professor Ursula Schmidt-Erfurth. The first results are already available: ‘The algorithms we developed need three exams to reliably predict the retinal status at the next scheduled exam and to predict whether the patient will suffer a relapse in the course of treatment,’ Dr Waldstein explains. These preliminarily tested methods must now be applied to large patient cohorts. ‘We delivered the proof of principle and expect prototypes for the large-scale evaluation to be available in one to two years.’

It may well be that the physician will not be able to comprehend the calculated results based on the algorithms. ‘The parameters that lead to the predictions might be highly complex,’ Waldstein says. ‘The analysis of big data is often a black box method. In short: the prediction is correct, but we don’t understand why.’ Dr Waldstein aims to provide software integrated into the OCT system, to offer a score or probability for the outcome that allows a physician to select the best possible treatment.


PROFILE:
Based in the Department of Ophthal­mology and Optometry at the Medical University of Vienna, ophthalmologist Sebastian M Waldstein also leads research on macular degeneration at the Vienna Reading Centre (VRC). Additionally, supervised by Professor Ursula Schmidt-Erfurth, he coordinates the Christian Doppler Laboratory for Ophthalmological Image Analysis, a publicly funded, inter­disciplinary research group set up to develop innovative computer-based methods to analyse large clinical image data sets. A native of Salzburg, Dr Waldstein studied medicine in Innsbruck and Vienna. Subsequently he has received prizes and awards from international professional associations such as ARVO, Max Kade Fellowship and ESASO.

28.04.2015

Read all latest stories

Related articles

Photo

Glioblastoma

New actively personalized therapeutic vaccine for brain cancer

The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the recent publication in Nature of favorable data from the phase 1 study GAPVAC-101,…

Photo

New therapies, new questions

To understand an image is to understand the treatment

Conventional chemotherapy in oncology is increasingly yielding to new procedures such as targeted therapy and immunotherapy. This results in changes for radiologists because new procedures require…

Photo

Advanced techniques

Breast cancer: how imaging technology will help avoid unnecessary biopsies

Enhancing the diagnosis of breast cancer is the stated goal of a research team at the German Cancer Research Center (DKFZ) in Heidelberg. The scientists have combined an advanced method of…

Related products